CL2011001356A1 - Formas cristalinas a1, h1, nf3 y nf6 de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il)-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo; proceso de preparacion; composicion y combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento o profilaxis de cancer, tumores, sarcoma, entre otros. - Google Patents

Formas cristalinas a1, h1, nf3 y nf6 de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il)-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo; proceso de preparacion; composicion y combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento o profilaxis de cancer, tumores, sarcoma, entre otros.

Info

Publication number: CL2011001356A1
Authority: CL; Chile
Prior art keywords: benzonitrile; piperidin; oxo; cancer; methyl
Prior art date: 2009-01-08

Application number

CL2011001356A

Other languages

English (en)

Spanish (es)

Inventor

Clemens Kuehn

Christoph Saal

Oliver Schadt

Dieter Dorsch

Axel Becker

Heinz-Hermann Bokel

Frank Stieber

Christina Donini

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-08

Filing date

2011-06-06

Publication date

2011-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001356(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-06-06 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2011-09-30 Publication of CL2011001356A1 publication Critical patent/CL2011001356A1/es

Links

206010028980 Neoplasm Diseases 0.000 title abstract 3
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
239000013078 crystal Substances 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title abstract 2
238000011282 treatment Methods 0.000 title abstract 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title 1
206010039491 Sarcoma Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
238000011321 prophylaxis Methods 0.000 title 1
238000012986 modification Methods 0.000 abstract 2
108091000080 Phosphotransferase Proteins 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
230000026683 transduction Effects 0.000 abstract 1
238000010361 transduction Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CL2011001356A 2009-01-08 2011-06-06 Formas cristalinas a1, h1, nf3 y nf6 de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il)-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo; proceso de preparacion; composicion y combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento o profilaxis de cancer, tumores, sarcoma, entre otros. CL2011001356A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP09000140		2009-01-08

Publications (1)

Publication Number	Publication Date
CL2011001356A1 true CL2011001356A1 (es)	2011-09-30

Family

ID=41572530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2011001356A CL2011001356A1 (es)	2009-01-08	2011-06-06	Formas cristalinas a1, h1, nf3 y nf6 de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il)-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo; proceso de preparacion; composicion y combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento o profilaxis de cancer, tumores, sarcoma, entre otros.

Country Status (31)

Country	Link
US (3)	US8710058B2 (pt)
EP (1)	EP2373640B1 (pt)
JP (2)	JP5719781B2 (pt)
KR (2)	KR101730791B1 (pt)
CN (1)	CN102272121B (pt)
AR (1)	AR074996A1 (pt)
AU (1)	AU2009336839B2 (pt)
BR (1)	BRPI0922642B8 (pt)
CA (4)	CA2749012C (pt)
CL (1)	CL2011001356A1 (pt)
CO (1)	CO6400191A2 (pt)
CY (1)	CY1115631T1 (pt)
DK (1)	DK2373640T3 (pt)
EA (1)	EA019342B1 (pt)
EC (1)	ECSP11011248A (pt)
ES (1)	ES2522629T3 (pt)
HR (1)	HRP20140908T1 (pt)
IL (1)	IL213829A0 (pt)
MX (3)	MX350894B (pt)
MY (1)	MY160017A (pt)
NZ (1)	NZ594404A (pt)
PE (2)	PE20141317A1 (pt)
PL (1)	PL2373640T3 (pt)
PT (1)	PT2373640E (pt)
SG (2)	SG172831A1 (pt)
SI (1)	SI2373640T1 (pt)
SM (1)	SMT201400161B (pt)
TW (1)	TWI475997B (pt)
UA (1)	UA106220C2 (pt)
WO (1)	WO2010078897A1 (pt)
ZA (1)	ZA201105782B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010078897A1 (en) *	2009-01-08	2010-07-15	Merck Patent Gmbh	Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
WO2013139423A1 (en) *	2012-03-19	2013-09-26	Merck Patent Gmbh	Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
PL2914264T3 (pl) *	2012-11-02	2017-12-29	Merck Patent Gmbh	Pochodna 6-okso-1,6-dihydropirydazyny do zastosowania w leczeniu raka wątrobowokomórkowego (hcc)
MY191613A (en) *	2014-01-07	2022-07-03	Merck Patent Gmbh	A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
MX2017007372A (es)	2014-12-12	2017-11-06	Merck Patent Gmbh	Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cancer con un inhibidor de factor de crecimiento epidermico (egfr).
WO2016155655A1 (zh)	2015-04-03	2016-10-06	上海瑛派药业有限公司	Parp抑制剂固体药物剂型及其应用
WO2016192831A1 (en)	2015-05-29	2016-12-08	Merck Patent Gmbh	Compositions of anions and cations with pharmacological activity
KR20180092096A (ko)	2017-02-08	2018-08-17	에이비온 주식회사	트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
IL278281B2 (en) *	2018-04-26	2025-01-01	Fujian Cosunter Pharmaceutical Co Ltd	Crystalline form of C–MET inhibitor and its salt form and method for preparing them
US20220288068A1 (en) *	2019-07-10	2022-09-15	Merck Patent Gmbh	Pharmaceutical preparation
WO2021147968A1 (zh)	2020-01-21	2021-07-29	正大天晴药业集团股份有限公司	一种irak4抑制剂的结晶及其制备方法
WO2022063869A2 (en)	2020-09-24	2022-03-31	Merck Patent Gmbh	Compounds for the treatment of viral infections
WO2022250350A1 (ko)	2021-05-26	2022-12-01	주식회사 이노큐어테라퓨틱스	피페리딘디온 유도체
KR102489160B1 (ko)	2021-05-26	2023-01-18	주식회사 이노큐어테라퓨틱스	피페리딘디온 유도체
EP4599885A3 (en)	2021-06-04	2025-10-15	Merck Patent GmbH	Compounds for the treatment of glioblastoma
CN114394957B (zh) *	2021-12-24	2023-05-09	武汉九州钰民医药科技有限公司	Met抑制剂盐酸特泊替尼的制备方法
KR20230155324A (ko)	2022-05-03	2023-11-10	주식회사 이노큐어테라퓨틱스	피페리딘디온 유도체
CN116768868B (zh) *	2023-08-15	2023-12-08	云南省药物研究所	一种哒嗪酮硫代衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7169932B2 (en) *	2001-06-11	2007-01-30	Pfizer Inc.	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
US7094909B2 (en) *	2001-06-11	2006-08-22	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
PL1658079T3 (pl) *	2003-08-19	2012-09-28	Pharmaton Sa	Syrop wielowitaminowy dla dzieci lub młodzieży
WO2005026114A1 (en) *	2003-09-17	2005-03-24	Pfizer Inc.	Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
TW200616634A (en) *	2004-10-01	2006-06-01	Bristol Myers Squibb Co	Crystalline forms and process for preparing spiro-hydantoin compounds
MX2007004783A (es) *	2004-10-21	2007-05-11	Pfizer	Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
CN101052633A (zh) *	2004-11-02	2007-10-10	辉瑞大药厂	制备吲唑化合物的方法
MX2007005291A (es) *	2004-11-02	2007-07-19	Pfizer	Metodos para preparar compuestos de indazol.
DE102005057924A1 (de) *	2005-12-05	2007-06-06	Merck Patent Gmbh	Pyridazinonderivate
TW200801012A (en) *	2006-04-26	2008-01-01	Piramed Ltd	Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7812032B2 (en) *	2006-07-25	2010-10-12	Abbott Laboratories	Crystalline forms of rapamycin analogs
US7820812B2 (en) *	2006-07-25	2010-10-26	Abbott Laboratories	Methods of manufacturing crystalline forms of rapamycin analogs
DE102007032507A1 (de)	2007-07-12	2009-04-02	Merck Patent Gmbh	Pyridazinonderivate
WO2010078897A1 (en) *	2009-01-08	2010-07-15	Merck Patent Gmbh	Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

2009
- 2009-12-04 WO PCT/EP2009/008684 patent/WO2010078897A1/en not_active Ceased
- 2009-12-04 MY MYPI2011003154A patent/MY160017A/en unknown
- 2009-12-04 EA EA201101039A patent/EA019342B1/ru not_active IP Right Cessation
- 2009-12-04 PE PE2013002901A patent/PE20141317A1/es not_active Application Discontinuation
- 2009-12-04 BR BRPI0922642A patent/BRPI0922642B8/pt active IP Right Grant
- 2009-12-04 CA CA2749012A patent/CA2749012C/en active Active
- 2009-12-04 DK DK09764204.5T patent/DK2373640T3/da active
- 2009-12-04 HR HRP20140908AT patent/HRP20140908T1/hr unknown
- 2009-12-04 SG SG2011048576A patent/SG172831A1/en unknown
- 2009-12-04 KR KR1020117018389A patent/KR101730791B1/ko active Active
- 2009-12-04 SI SI200931038T patent/SI2373640T1/sl unknown
- 2009-12-04 NZ NZ594404A patent/NZ594404A/xx unknown
- 2009-12-04 UA UAA201109704A patent/UA106220C2/ru unknown
- 2009-12-04 PE PE2011001297A patent/PE20120474A1/es not_active Application Discontinuation
- 2009-12-04 CN CN200980154090.7A patent/CN102272121B/zh active Active
- 2009-12-04 CA CA3014648A patent/CA3014648C/en active Active
- 2009-12-04 PT PT97642045T patent/PT2373640E/pt unknown
- 2009-12-04 CA CA3097370A patent/CA3097370A1/en active Pending
- 2009-12-04 US US13/143,831 patent/US8710058B2/en active Active
- 2009-12-04 EP EP09764204.5A patent/EP2373640B1/en active Active
- 2009-12-04 KR KR1020177010801A patent/KR101829595B1/ko active Active
- 2009-12-04 MX MX2011007322A patent/MX350894B/es active IP Right Grant
- 2009-12-04 CA CA2949515A patent/CA2949515C/en active Active
- 2009-12-04 ES ES09764204.5T patent/ES2522629T3/es active Active
- 2009-12-04 JP JP2011544793A patent/JP5719781B2/ja active Active
- 2009-12-04 MX MX2017012151A patent/MX363852B/es unknown
- 2009-12-04 AU AU2009336839A patent/AU2009336839B2/en active Active
- 2009-12-04 PL PL09764204T patent/PL2373640T3/pl unknown
- 2009-12-04 SG SG10201504735QA patent/SG10201504735QA/en unknown
- 2009-12-04 MX MX2017012152A patent/MX363848B/es unknown
- 2009-12-31 TW TW098146499A patent/TWI475997B/zh active
2010
- 2010-01-08 AR ARP100100033A patent/AR074996A1/es not_active Application Discontinuation
2011
- 2011-06-06 CL CL2011001356A patent/CL2011001356A1/es unknown
- 2011-06-28 IL IL213829A patent/IL213829A0/en active IP Right Grant
- 2011-07-11 CO CO11085919A patent/CO6400191A2/es not_active Application Discontinuation
- 2011-08-05 ZA ZA2011/05782A patent/ZA201105782B/en unknown
- 2011-08-05 EC EC2011011248A patent/ECSP11011248A/es unknown
2014
- 2014-01-17 US US14/158,182 patent/US9289427B2/en active Active
- 2014-10-15 CY CY20141100845T patent/CY1115631T1/el unknown
- 2014-10-30 SM SM201400161T patent/SMT201400161B/xx unknown
- 2014-11-14 JP JP2014231814A patent/JP5860126B2/ja active Active
2015
- 2015-01-29 US US14/609,137 patent/US9308205B2/en active Active

Also Published As

Publication number	Publication date
JP2012514609A (ja)	2012-06-28
CA2749012A1 (en)	2010-07-15
JP5860126B2 (ja)	2016-02-16
KR20170047408A (ko)	2017-05-04
PT2373640E (pt)	2014-09-30
NZ594404A (en)	2013-04-26
UA106220C2 (ru)	2014-08-11
JP5719781B2 (ja)	2015-05-20
US20110269767A1 (en)	2011-11-03
EP2373640A1 (en)	2011-10-12
SMT201400161B (it)	2015-01-15
MX363848B (es)	2019-04-05
MX2011007322A (es)	2011-07-29
SG172831A1 (en)	2011-08-29
MY160017A (en)	2017-02-15
ECSP11011248A (es)	2011-10-31
WO2010078897A1 (en)	2010-07-15
CA3014648A1 (en)	2010-07-15
IL213829A0 (en)	2011-07-31
CA3097370A1 (en)	2010-07-15
KR101730791B1 (ko)	2017-04-27
CA2949515A1 (en)	2010-07-15
KR20110111472A (ko)	2011-10-11
AU2009336839A8 (en)	2011-09-08
TW201029655A (en)	2010-08-16
PL2373640T3 (pl)	2014-12-31
US9289427B2 (en)	2016-03-22
EA019342B1 (ru)	2014-02-28
AU2009336839B2 (en)	2015-12-24
ES2522629T3 (es)	2014-11-17
CN102272121B (zh)	2014-12-10
US20140200221A1 (en)	2014-07-17
HK1164856A1 (en)	2012-09-28
TWI475997B (zh)	2015-03-11
CA2749012C (en)	2017-01-31
US20150148351A1 (en)	2015-05-28
KR101829595B1 (ko)	2018-02-14
MX363852B (es)	2019-04-05
BRPI0922642B1 (pt)	2020-09-29
EP2373640B1 (en)	2014-07-30
US9308205B2 (en)	2016-04-12
HRP20140908T1 (hr)	2014-11-07
SG10201504735QA (en)	2015-07-30
ZA201105782B (en)	2012-04-25
MX350894B (es)	2017-09-22
PE20141317A1 (es)	2014-09-26
CO6400191A2 (es)	2012-03-15
US8710058B2 (en)	2014-04-29
AR074996A1 (es)	2011-03-02
BRPI0922642A2 (pt)	2016-01-05
CY1115631T1 (el)	2017-01-04
CA3014648C (en)	2021-06-01
AU2009336839A1 (en)	2011-08-25
JP2015038148A (ja)	2015-02-26
CA2949515C (en)	2018-10-23
CN102272121A (zh)	2011-12-07
DK2373640T3 (da)	2014-10-06
SI2373640T1 (sl)	2014-11-28
PE20120474A1 (es)	2012-05-04
BRPI0922642B8 (pt)	2021-05-25
EA201101039A1 (ru)	2012-02-28

Publication	Publication Date	Title
CL2011001356A1 (es)	2011-09-30	Formas cristalinas a1, h1, nf3 y nf6 de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il)-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo; proceso de preparacion; composicion y combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento o profilaxis de cancer, tumores, sarcoma, entre otros.
ECSP20018487A (es)	2020-05-29	Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
ECSP099634A (es)	2009-10-30	Derivados de piridazinona útiles como inhibidores de glucano sintasa
CL2009000860A1 (es)	2010-05-07	Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
CO6170360A2 (es)	2010-06-18	Derivados de pirimidinil - piridazinona
CL2009000483A1 (es)	2010-02-19	Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
MX2017013886A (es)	2018-03-12	Azabenzimidazoles y su uso como moduladores del receptor ampa.
CO6612243A2 (es)	2013-02-01	Derivados de [1.8]naftiridina
CL2011000570A1 (es)	2011-06-17	Compuestos derivados de 3-(4-ciano-fenil)-pirazol-5-carboxamida, moduladores del receptor de progesterona; composicion farmaceutica; y su uso para el tratamiento de endometriosis, fibromiomas uterinos, dismenorrea primaria o secundaria, entre otras.
CL2008002243A1 (es)	2009-08-21	Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
DOP2011000279A (es)	2011-10-15	Derivados de benzofuranilo usados como inhibidores de glucoquinasa
ECSP099776A (es)	2010-01-29	Moduladores de la gamma secretasa
CU20060037A7 (es)	2008-06-30	Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BR112015007937A2 (pt)	2017-07-04	formas cristalinas de um inibidor de fator xia
ECSP099574A (es)	2009-09-29	Agonistas adrenoreceptores alfa2c
CL2009000368A1 (es)	2009-06-26	3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3.
CO7350641A2 (es)	2015-08-10	Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
CU20100035A7 (es)	2011-09-21	Derivados de ciclopropilamida como moduladores h3
CL2008000202A1 (es)	2009-10-02	Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
MX2017013874A (es)	2018-06-22	Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CL2009000084A1 (es)	2009-03-20	Compuestos derivados de sulfonamida sustituida, moduladores de receptores de bradiquinina; composicion farmaceutica que contiene a los compuestos; y uso en el tratamiento del dolor agudo, neuropatico o cronico, entre otros.
ECSP099579A (es)	2009-09-29	Agonistas de adrenoreceptores alfa2c funcionalmente selectivos
CL2016001342A1 (es)	2016-11-18	Formas cristalinas hemihidrato y anhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que las comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras.
CL2012001606A1 (es)	2012-10-05	Compuestos derivados de tiazoles bicíclicos como moduladores alostéricos de receptores mglur5; composición farmacéutica que los comprende; procedimiento de preparación de la composición farmacéutica; combinación farmacéutica; y uso del compuesto en la prevención, tratamiento o profilaxis de trastornos neurológicos o psiquiátricos.
CL2009001282A1 (es)	2009-10-23	Compuestos derivados de pirrolidin amidas sustituidas, moduladores del receptor de histamina h3; composicion farmaceutica que los contiene; y su uso para el tratamiento de enfermedades tales como demencia, alzheimer, disfuncion cognitiva, trastorno de la memoria, trastorno de aprendizaje, deficit atencional, entre otras.